State of Wyoming Takes $293,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

State of Wyoming bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 14,806 shares of the company's stock, valued at approximately $293,000.

Several other large investors have also recently bought and sold shares of KNSA. SG Americas Securities LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter worth approximately $355,000. China Universal Asset Management Co. Ltd. raised its position in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after acquiring an additional 1,004 shares in the last quarter. Peregrine Capital Management LLC lifted its stake in Kiniksa Pharmaceuticals by 1.8% in the fourth quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company's stock valued at $4,827,000 after acquiring an additional 4,361 shares during the last quarter. New York State Common Retirement Fund lifted its stake in Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock valued at $302,000 after acquiring an additional 1,680 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at about $258,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KNSA has been the topic of several recent analyst reports. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Finally, Wedbush restated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $38.80.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CFO Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total value of $809,277.00. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $510,815.50. The trade was a 61.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sanj K. Patel sold 2,872 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $27.03, for a total value of $77,630.16. Following the completion of the sale, the chief executive officer now owns 96,674 shares of the company's stock, valued at approximately $2,613,098.22. This trade represents a 2.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 243,640 shares of company stock worth $5,986,056 in the last ninety days. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Trading Up 3.6%

NASDAQ:KNSA traded up $0.94 on Friday, hitting $26.89. The company's stock had a trading volume of 590,247 shares, compared to its average volume of 488,329. The stock has a fifty day moving average of $23.26 and a two-hundred day moving average of $21.48. The firm has a market capitalization of $1.96 billion, a P/E ratio of -192.06 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a one year low of $17.38 and a one year high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the prior year, the company earned ($0.25) earnings per share. The business's revenue for the quarter was up 72.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.